The FDA Is Reviewing 7 Popular Peptides. A Cardiologist Explains What's at Stake.
FDA / PCAC — official records & coverage — The FDA Is Reviewing 7 Popular Peptides. A Cardiologist Explains What's at Stake.
Channel: Amy Pearlman, M.D. · Our label: Government proceedings and coverage of them · Source: youtube.com/watch?v=KhSH97MNIVU
What this video covers
I’m a board certified urologist and we are talking about peptides today and I have Dr. I’m a board certified cardiologist work out at Boulder Longevity Institute. And I wanted to chat with you today because you were going to be one of the key people testifying during the upcoming hearing on peptides trying to reclassify. How did you get involved in the peptide space?
Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.
Key points, in the speaker’s own framing
- So, arguably, you probably have as a healthcare provider some of the most experience in the peptide space out of all healthcare providers.
- So 10 years ago because I know that you make decisions based on evidence and 10 years ago there was less evidence than there is now in terms of peptides.
Well, the worst thing I’ve seen isn’t actually FDA approved peptides and which is which which is fascinating and sort of counterintuitive.
- you know it the that that formulary is relatively safe and and much safer than what we see happening with GLP1s even though that got approved.
- By far, the safety profile is so much safer for peptides than some of the major most prescribed medications we have available.
- So, we get this message that peptides, you know, danger, danger, danger zone.
Read next
Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.